InvestorsHub Logo
Followers 9
Posts 785
Boards Moderated 0
Alias Born 04/01/2014

Re: docsetc post# 198192

Monday, 05/20/2024 5:57:50 PM

Monday, May 20, 2024 5:57:50 PM

Post# of 198739
Found the $360 million. It's on page 23. It's funny I thought the deal was valued at $450 million at the time. I must have missed the PR about the change in transaction price.

On September 18, 2023, the Company executed and closed a definitive business
combination agreement with Sagaliam Acquisition Corp. selling the operating
subsidiaries Virogenetics, Inc. and Biogenysis, Inc. in a stock transaction valued at
$360 million. This left the Company with no operating subsidiaries. The Company is
currently formulating a new business strategy and searching for target acquisitions